Mechanisms of resistance to anticancer drugs in digestive;Mecanismes de la chimioresistance au cours des cancers digestifs

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 2, 1998, Pages 132-143

  Grude, Pascale ^a   Conti, Filomena ^a   Molinier, Nathalie ^a   Chaussade, Stanislas ^a   Calmus, Yvon ^a  

^a Institut Cochin   (France)

Author keywords

Anticancer therapy; Apoptosis; Cell cycle; Chemoresistance; Digestive cancers; MDR

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRAQUINONE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; ANTINEOPLASTIC ANTIBIOTIC; CHLORPROMAZINE; CISPLATIN; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; MELPHALAN; METHOTREXATE; NIFEDIPINE; PACLITAXEL; PODOPHYLLOTOXIN; QUINIDINE; QUININE; RIFAMPICIN; TAMOXIFEN; TOREMIFENE; TRIFLUOPERAZINE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

APOPTOSIS; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GENE THERAPY; HUMAN; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS CANCER; REVIEW; STOMACH CANCER; DIGESTIVE SYSTEM TUMOR; DNA REPAIR; DRUG RESISTANCE; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DIGESTIVE SYSTEM NEOPLASMS; DNA REPAIR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 0031991921     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowski A, Roessner A. Reverse transcriptase-polymerase chain reaction amplification of MDRI gene expression in adult soft tissue sarcomas. Diagn Mol Pathol 1996;5:98-106.
2. Muller C, Staumont G, Bradley G, Bibeau F, Brousset P, Laurent G. Expression de la P-glycoprotéine dans le tube digestif et le foie. Implications dans la physiologie cellulaire. Gastronterol Clin Biol 1992;16:791-7.
3. Chin JE, Soffir R, Noonan KE, Choik K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989;9:3808-20.
4. Sugarawa I, Kataooka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody MRK16. Cancer Res 1988;48:4611-4.
5. Joly B, Fardel O, Cecchelli R, Chesne C, Puozzo C, Guillouzo A. Selective drug transport and P-glycoprotein activity in an in vitro blood-brain barrier model. Toxicol in Vitro 1995;9:357-64.
6. Leighton JC, Goldstein U. P-glycoprotein in adult solid tumors. Hematol Oncol Clin North Am 1995;9:251-73.
7. Schuetz EG, Furuya N, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995;275:1011-8.
8. Itsubo M, Ishikawa T, Toda G, Tanaka M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 1994;73:298-303.
9. Soini Y, Virkajärvi N, Raunio H, Pääkkö P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 1996;49:470-3.
10. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino R, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-87.
11. Linn SC, Giaccone G. MDRI/P-glycoprotein expression in colorectal cancer. Eur J Cancer 1995;31A:1291-4.
12. Ikeguchi M, Shirai H, Kaibara N, Ito H. Expression of P-glycoprotein in the normal colorectal epithelium and in colorectal carcinoma. Int J Oncol 1995;7:319-24.
13. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst 1989;81:116-24.
14. Peters WH, Boon CE, Roelofs HM, Wobbes T, Nagengast FM, Kremers PG. Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology 1992;103:448-55.
15. Roninson IB. The role of the MDRI (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 1992;43:95-102.
16. Sharom FJ, DiDiodato G, Yu X, Ashbourne KJD. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J Biol Chem 1995;270:10334-41.
17. Lehnert N. Multidrug resistance in human cancer. J Neurooncol 1994;22:239-43.
18. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in vinca alcaloid-resistant human leukemic lymphoblasts. Cancer Res 1979;39:2070-6.
19. Gottesman MM, Pastan I. Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol Sci 1988; 9:54-8.
20. Biedler JL, Riemh H. Cellular resistance to actinomycin D in chinese hamster cells in vitro: cross resistance, radioautographic and cytogenetic studies. Cancer Res 1970;30:1164-74.
21. Juliano RL, Ling V. A surface glycoprotein drug permeability in chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-62.
22. Gant TW, Silverman JA, Bisgaard HC, Burt RK, Marino PA, Thorgeirsson SS. Regulation of 2-acetylaminofluorene and 3-methylcholanthrene-mediated induction of multidrug resistance and cytochrome P450 IA gene family expression in primary hepatocytes cultures and rat liver. Mol Carcinog 1991;4:499-509.
23. Burt RK, Thorgeirsson SS. Coinduction of MDR-I multidrug resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst 1988;80:1383-6.
24. Cole SP, Bhardwa JG, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258:1650-4.
25. Krishnamachary N, Center MS. The MRP gene associated with a non P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993;53:3658-61.
26. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SP, et al. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 1995;55:459-62.
27. Chuman Y, Sumizawa T, Takebayashi Y, Niwa K, Haraguchi M, Furukawa T, et al. Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 1996;66:274-9.
28. Mayer R, Kartenbeck J, Buchler M, Jedlitschky G, Leier I, Keppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 1995;131:137-50.
29. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, et al. The drug resistance-related protein LRP is the human major vault protein. Nature 1995;1:578-82.
30. Bénard J, Rixe O. Résistance aux drogues anticancéreuscs. Presse Med 1996;25:1724-30.
31. Lu YZ, Aiello PD, Matthews RG. Studies on the polyglutamate specificity of thymidilate synthetase from fetal pig liver. Biochemistry 1984;23:6870-6.
32. Chéradame S, Etienne MC, Chazal M, Guillot T, Fischel JL, Formento P, et al. Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal fluorouracil efficacy. Experimental data. Eur J Cancer 1997;33:950-9.
33. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach. A predictor for primary tumor response and overall survival. J Clin Oncol 1995;14:176-82.
34. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 1989;16:215-37.
35. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
36. Yin MB, Zakrzewski S, Hakala MT. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 1983;23:190-7.
37. Berger SH, Jenh CH, Johnson LF, Berger FG. Thymidilate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985;28:461-7.
38. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidilate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-42.
39. Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg K, Baranda J, et al. Quantitation of intratumoral thymidilate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers. Preliminary report from an ongoing trial. Eur J Cancer 1995;31A:1306-10.
40. McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 1996;41:425-7.
41. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986;6: 781-4.
42. Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Guillot T. Wide range for optimal concentration of folinic acid in fluorouracil modulation. Experimental data on human tumor cell lines. Eur J Cancer 1994;30A:1522-6.
43. Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-70.
44. Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993;29A:740-4.
45. Rougier P, Ducreux M. Optimiser la chimiothérapie dans les cancers digestifs. L'exemple des cancers colorectaux métastasés. Hépato-Gastro 1997;4:91-101.
46. Tuchman M, Ramnaraine ML, O'Dea RF. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil and thymine by rat liver dihydropyrimidine dehydrogenase. Cancer Res 1985; 45:5553-6.
47. Houyau P, Gay C, Chatelut E, Canal P, Roche H, Milano G. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 1993;85:1602-3.
48. Ketterer B, Meyer DJ, Klark A. Soluble glutathione transferase isoenzymes. In: Glutathione conjugation. Mechanisms and biological significance. Sies H, Ketterer B, eds. London: Academic Press, 1988: 73-125.
49. Meyer DJ, Beale D, Tan KH, Coles B, Ketterer B. Glutathione transferase in primary rat hepatomas. The isolation of a form with GSH peroxidase activity. FEBS Lett 1985;184:139-43.
50. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic resistant glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986;261:15544-9.
51. Gupta V, Singh SV, Ahmad H, Medh RD, Awasthi YC. Glutathione and glutathione-S-transferase in a human plasma cell line resistant to mephalan. Biochem Pharmacol 1989;38:1993-2000.
52. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M. Insights into mechanisms of cisplatine resistance and potential for its clinical reversal. Pharmacotherapy 1996;16:16-39.
53. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994;54:5255-7.
54. Sekigushi M, Nakabeppu Y. Adaptative response: induced synthesis of DNA repair enzymes by alkylating agents. Trends Genet 1987;3:51-4.
55. 6-methylguanine-DNA methyltransferase activity in transgenic mice containing an integrated E.coli ada repair gene. Mutat Res 1989;218:197-206.
56. 6-methylguanine-DNA methyltransferase in transgenic mice introduced with the E.coli ada gene. Mutat Res 1991; 254:225-30.
57. 6-methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc Natl Acad Sci USA 1993;90:6468-72.
58. 6-methylguanine-DNA alkyltransferase. Science 1993;259:219-22.
59. 6-methylguanine-DNA methyltransferase-expression in human tumors by means of in situ hybridization. Anticancer Res 1995;15: 761-7.
60. 6-alkylguanine-DNA alkyltransferase gene in normal breast and skin tissue: in situ mapping of cell type-specific expression. Mol Carcinog 1995;12:177-84.
61. Payne CM, Bernstein H, Bernstein C, Garewal H. Role of apoptosis in biology and pathology. Resistance to apoptosis in colon carcinogenesis. Ultrastruct Pathol 1995;19:221-48.
62. Magnuson BA, Shirtliff N, Bird RP. Resistance of aberrant crypt foci to apoptosis induced by azoxymethane in rats chronically fed cholic acid. Carcinogenesis 1994;15:1459-62.
63. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49-53.
64. Nabeya Y, Loganzo F, Maslak P, Lai L, De Oliveira AR, Schwartz GK, et al. The mutational status of P53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995;64:37-46.
65. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
66. Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 1996;73: 610-4.
67. Gottlieb JA, Luce JK. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 1972;56: 103-5.
68. Giaccone G, Vanarkotte J, Scagliotti G, Capranico G, Vandervalk P, Rubio G, et al. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1995;1264:337-46.
69. Creemerst GJ, Lund B, Verweij T. New drugs. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994;20: 73-96.
70. Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gene Pharmacol 1996;27:251-5.
71. Jacquemin-Sablon A, Bojanowski K, Casabianca-Pignède MR, Crémier S, Delaporte C, Khelifa T, et al. Résistance cellulaire aux inhibiteurs de la topo-isomérase II Bull Cancer (Paris) 1994;81: 381-5.
72. Chauffert B. Résistance aux médicaments anticancéreux: approches théoriques et expérimentales. Hépato-Gastro 1997;4:102-9.
73. Edmonson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48900 necropsies. Cancer 1954;7:462-503.
74. Chin KW, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDRI gene by Ras and p53. Science 1992;255:459-62.
75. Itsubo M, Toda G. Immunohistochemical study of expression of P-glycoprotein and mutant p53 protein in hepatocellular carcinoma from the viewpoint of modulation of transcriptional activity of MDRI gene. Int Hepatol Commun 1996;5:317-25.
76. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993;29A:2077-9.
77. Dukes CE. The classification of cancer of the rectum. J Pathol 1932;35:323-32.
78. Goodman GE, Yen YP, Cox TC, Crowley J. Effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells. Cancer Res 1987;47:2295-304.
79. Herzog CE, Trepel JB, Mickey LA, Bates SE, Fojo AT. Various methods of analysis of mdrI/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst 1992;84:711-6.
80. Johnston PG, Fisher E, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidilate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
81. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8.
82. Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, et al. P53 nuclear protein overexpression in colorectal cancer. A dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996;14:2696-701.
83. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Leichman L. Thymidilate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
84. Inaba M, Junko M, Hiroko S, Miike N, Naoe Y, Daimon A, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 1996;87: 212-20.
85. Tsuruo T, Lida H, Teukagothl S, Sakurai V. Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982;42:4730-3.
86. Tsuruo T, Iida H, Kititani Y, Yokata K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 1984;44:4303-7.
87. Christen RD, McClay EF, Plaxe SC, Yen SS, Kim S, Kirmani S, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicine. J Clin Oncol 1993;11:2417-26.
88. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine cells by tamoxifen and other triparanol analogues. Cancer Res 1984;44:4392-5.
89. Twentyman PR. Cyclosporine as drug resistance modiflore. Biochem Pharmacol 1992;43:109-17.
90. Sonneveld P, Durie BGM, Lokhorst HM, Maric T, Soebu G, Sucin S, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-9.
91. Fardel O, Lecureur V, Loyer P, Guillouzo A. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol 1995;49:1255-60.
92. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992;89:5824-8.
93. Merlin JL, Marchal S, Ramacci C, Dieterlen A, Schultz G, Lucas C, et al. Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicine in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells. Cytometry 1995;20:315-23.
94. Jiang XR, Kelsey SM, Wu YL, Newland AC. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Br J Haematol 1995;90:375-83.
95. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-9.
96. Fardel O, Loyer P, Morel F, Ratanasavanh D, Guillouzo A. Modulation of multidrug gene expression in rat hepatocytes maintained under various culture conditions. Biochem Pharmacol 1992;44:2259-62.
97. Fardel O, Lécureur V, Guillouzo A. Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett 1993;327:189-93.
98. Ford IM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;171:1002-7.
99. Miller TP, Grogan TM, Dalton E, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 1991;9:17-24.
100. Lécureur V, Fardel O, Guillouzo A. The antiprogestatin drug RU486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 1994;355:187-91.
101. Sola JE, Colombani PM. Modulation of multidrug resistance with antisense oligodeoxynucleotide to MDRI mRNA. Ann Surg Oncol 1996;3:80-5.
102. Warren L, Jardiller JC, Malarska A, Akelli MG. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes. Cancer Res 1992;52:3241-5.
103. Hu YP, Jarillon S, Dubernet C, Couvreur P, Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother Pharmacol 1996;37:556-60.
104. De Gramont A, Louvet C, André T, Tournigand C, Raymond E, Krulik M. Chimiothérapie des cancers colorectaux avec métastases. Presse Med 1996;25:1678-82.
105. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-atlantic oncology program study. J Clin Oncol 1989;7:425-32.
106. Daher GC, Naguib FNM, El Kouni MH, Zhang R, Soong SJ, Diasio RB. Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. Biochem Pharmacol 1991;41:1887-93.
107. Porter D, Chestnut W, Merrill B, Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992;267:5236-42.
108. Milano G, Etienne MC, Fischel JL. Intratumoral dihydropyrimidine dehydrogenase and its inhibition: a new approach in the pharmacokinetics of 5-fluorouracil. Ann Gastroenterol Hepatol 1995;31:103-5.
109. Spector T, Harrington J, Porter DJ. 5-ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993;46:2243-8.
110. Cao S, Rustum YM, Spector T. 5-ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54: 1507-10.
111. Khor SP, Amyx H, Davis ST, Nelson D, Baccanari DP, Spector T. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics-allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. Cancer Chemother Pharmacol 1997;39:233-8.
112. De Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hours continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
113. Baccanari DP, Davis ST, Knick VC, Spector T. 5-ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993;90:11064-8.
114. Cao S, Baccanari DP, Joyner SS, Davis ST, Rustum YM, Spector T. 5-ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cancer Res 1995;55:6227-30.
115. Guo X, Lerner-Tung M, Chen XM, Chang CN, Zhu JL, Chang CP, et al. 5-fluoro-2-pyrimidone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil. Biochem Pharmacol 1995;49:1111-6.
116. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, et al. A phase II study of combination therapy with 5'-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993;72:658-62.
117. Rougier P, Bugat R, Douillard JY, Culine S, Sue E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
118. Morgan AS, Ciaccio PJ, Tew KD, Kauvar LN. Isozyme specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chem Pharmacol 1996; 37:363-70.
119. Caliaro MJ, Vitaux P, Lafon C, Lochon I, Nehme A, Valette A, et al. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer 1997;75:333-40.
120. Fruehauf S, Breems DA, Knaän-Shanzer S, Brouwer KB, Haas R, Löwenberg B, et al. Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. Hum Gene Ther 1996;7:1219-31.
121. Aksentijevich I, Pastan I, Lunardi-Iskandar Y, Gallo RC, Gottesman MM, Thierry AR. In vitro and in vivo liposome mediated gene transfer leads to human MDRI expression in mouse bone marrow progenitor cells. Hum Gene Ther 1996;7:1111-22.
122. Spitz FR, Nguyen D, Skibber JM, Cusack J, Roth JA, Cristiano RJ. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996;16:3415-22.
123. Watson AJM. Manipulation of cell death. The development of novel strategies for the treatment of gastrointestinal disease. Aliment Pharmacol Ther 1995;9:215-26.
124. Andrews PA. Mechanisms of acquired resistance to cisplatin. Cancer Treat Res 1994;73: 217-48.
125. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. Pharmacol Ther 1991;52:385-406.
126. Hill BT. Interactions between antitumour agents and radiation and the expression of resistance. Cancer Treat Rev 1991;18:149-90.
127. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992;27:337-84.
128. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-8.
129. Unger C. Current concepts of treatment in medical oncology: new anticancer drugs. J Cancer Res Clin Oncol 1996;122:189-98.